A Phase 2 interventional study of DE-104 ophthalmic solution, low concentration and DE-104 ophthalmic solution, medium concentration in Open-Angle Glaucoma and Ocular Hypertension, sponsored by Santen Inc.. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-11-03.
Sponsored by Santen Inc. · Phase 2, Interventional, and Treatment
To investigate the dose-response relationship of DE-104 ophthalmic solution in lowering intraocular pressure (IOP) in subjects with Primary Open-Angle Glaucoma or Ocular Hypertension
1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.
This study's planned enrollment of 165 is above the median of 65 across 1,272 interventional studies indexed under Glaucoma.
Browse Glaucoma studies →Santen Inc. is the lead sponsor of 31 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
\<described in intervention\>
Drug: DE-104 ophthalmic solution, low concentration
\<described in intervention\>
Drug: DE-104 ophthalmic solution, medium concentration
\<described in intervention\>
Drug: DE-104 ophthalmic solution, high concentration
\<described in intervention\>
Drug: Placebo
\<described intervention\>
Drug: 0.005% latanoprost
Topical ocular application
Topical ocular application
Topical ocular application
placebo
Topical ocular application
To investigate the dose-response relationship of DE-104 in lowering intraocular pressure (IOP)
Time frame: 28 days
To compare the safety and efficacy of DE-104 ophthalmic solution with placebo and 0.005% latanoprost.
Time frame: 35 days
This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Santen Inc.